ArticleCancer discovery2015
A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 7 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 7 pooled it
9.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 7 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.Nature communications · 2023Pooled it
- Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.European urology · 2023Pooled it
- Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts.Nature communications · 2021Pooled it
- Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction.Nature genetics · 2021Pooled it
- Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB.Human molecular genetics · 2020Pooled it
- Genome-wide association study of INDELs identified four novel susceptibility loci associated with lung cancer risk.International journal of cancer · 2020Pooled it
- Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry.Journal of the National Cancer Institute · 2017Pooled it
- Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma.Scientific reports · 2019Trial
- Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.The Prostate · 2017Trial
- Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.Asian journal of andrologyTrial
- An artificial intelligence model integrating clinico-laboratory data and single nucleotide polymorphism-based genomic risk for prostate cancer diagnosis in Korean men.Investigative and clinical urology · 2026Article
- Incidence and Short- to Intermediate-Term Oncological Outcomes of Pathological T0 Prostate Cancer After Robot-Assisted Radical Prostatectomy: A Multicenter, Retrospective Cohort Study in Japan (MSUG94 Group).Current oncology (Toronto, Ont.) · 2026Article
- Incorporating external risk information with the Cox model under population heterogeneity: applications to trans-ancestry polygenic hazard scores.Journal of the Royal Statistical Society. Series A, (Statistics in Society) · 2026Article
- The castration-resistant prostate cancer-associated SNP rs11067228 facilitates neuroendocrine differentiation through an enhancer-mediated chromatin interaction with SRRM4.International journal of biological sciences · 2026Article
- Decoding the germline genetic architecture of prostate cancer at a single cell resolution.PLoS genetics · 2025Article
- Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors.Cancer medicine · 2025Review
- Integrative Transcriptome-Wide Association Study With Expression Quantitative Trait Loci Colocalization Identifies a Causal VAMP8 Variant for Nasopharyngeal Carcinoma Susceptibility.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer.Biomolecules · 2025Article
- Genome-Wide Association Study of Insertions and Deletions Identified Novel Loci Associated with Milk Production Traits in Dairy Cattle.Animals : an open access journal from MDPI · 2024Article
- Genetic Variants and Haplotype Structures in theHealth science reports · 2024Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 10 institutions in 3 countries.
Thomas J HoffmannDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California.
Stephen K Van Den EedenDivision of Research, Kaiser Permanente, Northern California, Oakland, California. Department of Urology, University of California, San Francisco, San Francisco, California. wittej@humgen.ucsf.edu Stephen.Vandeneeden@kp.org.
Lori C SakodaDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Eric JorgensonDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Laurel A HabelDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Rebecca E GraffDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Michael N PassarelliDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Clinton L CarioDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Nima C EmamiDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.
Chun R ChaoDepartment of Research and Evaluation, Kaiser Permanente, Southern California, Pasadena, California.
Nirupa R GhaiDepartment of Research and Evaluation, Kaiser Permanente, Southern California, Pasadena, California.
Jun ShanDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Dilrini K RanatungaDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Charles P QuesenberryDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
David AaronsonDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California.
Joseph PrestiDepartment of Urology, Kaiser Oakland Medical Center, Northern California, Oakland, California.
Zhaoming WangLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
Sonja I BerndtLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
Stephen J ChanockLaboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, NIH, Bethesda, Maryland.
Shannon K McDonnellDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Amy J FrenchDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Daniel J SchaidDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Stephen N ThibodeauDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Qiyuan LiMedical College, Xiamen University, Xiamen, China.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, Massachusetts. The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts.
Kathryn L PenneyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Brian E HendersonDepartment of Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California.
Daniela SeminaraNational Cancer Institute, NIH, Bethesda, Maryland.
Mark N KvaleInstitute for Human Genetics, University of California, San Francisco, San Francisco, California.
Pui-Yan KwokInstitute for Human Genetics, University of California, San Francisco, San Francisco, California.
Catherine SchaeferDivision of Research, Kaiser Permanente, Northern California, Oakland, California.
Neil RischDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California. Division of Research, Kaiser Permanente, Northern California, Oakland, California.
John S WitteDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California. Department of Urology, University of California, San Francisco, San Francisco, California. UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. wittej@humgen.ucsf.edu Stephen.Vandeneeden@kp.org.
Kaiser Permanente · USUniversity of California, San Francisco · USMayo Clinic · USDepartment of Health and Human Services · USBrigham and Women's Hospital · USKaiser Permanente Oakland Medical Center · USUniversity of Southern California · USDana-Farber Cancer Institute · USNational Cancer Institute · USXiamen University · CN
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MA Resource for Genetic Epidemiology Research in Adult Health and AgingRC2AG036607 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI RISCH, NEIL J., SCHAEFER, CATHERINE ANN · 2009 to 2010
$24.8MGENETIC SUSCEPTIBILITY TO CANCER IN MULTIETHNIC COHORTSR01CA063464 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HENDERSON, BRIAN E · 2001 to 2005
$23.2MMultiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2MBMI Bioinformatics Training GrantsT32GM067547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HERNANDEZ, RYAN D. · 2003 to 2022
$6.6MTraining in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5MGenetic Epidemiology of Prostate Cancer Risk and ProgressionR01CA088164 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VAN DEN EEDEN, STEPHEN K., WITTE, JOHN S. · 2000 to 2015
$6.1MGenomewide Association Study of Prostate CancerU01CA127298 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2008 to 2012
$5.1MMULTIETHNIC/MINORITY COHORT STUDY OF DIET AND CANCERR01CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 1993 to 2002
$4.5MMolecular Link Between Metabolic Syndrome and Prostate CancerR01CA131945 · NCI · DANA-FARBER CANCER INST · PI LODA, MASSIMO · 2008 to 2018
$4.0MIntegrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2MNCI NIH HHS CA088164NCI NIH HHS CA112355NCI NIH HHS CA127298NCI NIH HHS CA131945NCI NIH HHS CA1326792NCI NIH HHS CA136578NCI NIH HHS CA141298NCI NIH HHS CA148085NCI NIH HHS CA151254NCI NIH HHS CA157881NCI NIH HHS CA54281NCI NIH HHS CA63464NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA054281NCI NIH HHS R01 CA063464NCI NIH HHS R01 CA088164NCI NIH HHS R01 CA131945NCI NIH HHS R01 CA136578NCI NIH HHS R01 CA141298NCI NIH HHS R01 CA151254NCI NIH HHS R01 CA157881NCI NIH HHS R25 CA112355NCI NIH HHS R37 CA054281NCI NIH HHS RC2 CA148085NCI NIH HHS T32 CA112355NCI NIH HHS U01 CA063464NCI NIH HHS U01 CA127298NHGRI NIH HHS HG004726NHGRI NIH HHS U01 HG004726NIA NIH HHS AG046616NIA NIH HHS R21 AG046616NIA NIH HHS RC2 AG036607NIBIB NIH HHS T32 EB009383NIDCD NIH HHS DC013300NIDCD NIH HHS K01 DC013300NIGMS NIH HHS R01 GM107427NIGMS NIH HHS T32 GM067547
Abstract
unlabelledA genome-wide association study (GWAS) of prostate cancer in Kaiser Permanente health plan members (7,783 cases, 38,595 controls; 80.3% non-Hispanic white, 4.9% African-American, 7.0% East Asian, and 7.8% Latino) revealed a new independent risk indel rs4646284 at the previously identified locus 6q25.3 that replicated in PEGASUS (N = 7,539) and the Multiethnic Cohort (N = 4,679) with an overall P = 1.0 × 10(-19) (OR, 1.18). Across the 6q25.3 locus, rs4646284 exhibited the strongest association with expression of SLC22A1 (P = 1.3 × 10(-23)) and SLC22A3 (P = 3.2 × 10(-52)). At the known 19q13.33 locus, rs2659124 (P = 1.3 × 10(-13); OR, 1.18) nominally replicated in PEGASUS. A risk score of 105 known risk SNPs was strongly associated with prostate cancer (P < 1.0 × 10(-8)). Comparing the highest to lowest risk score deciles, the OR was 6.22 for non-Hispanic whites, 5.82 for Latinos, 3.77 for African-Americans, and 3.38 for East Asians. In non-Hispanic whites, the 105 risk SNPs explained approximately 7.6% of disease heritability. The entire GWAS array explained approximately 33.4% of heritability, with a 4.3-fold enrichment within DNaseI hypersensitivity sites (P = 0.004). SIGNIFICANCE: Taken together, our findings of independent risk variants, ethnic variation in existing SNP replication, and remaining unexplained heritability have important implications for further clarifying the genetic risk of prostate cancer. Our findings also suggest that there may be much promise in evaluating understudied variation, such as indels and ethnically diverse populations.
Indexed as
Genome-Wide Association StudyAdultAgedAllelesBiomarkers, TumorCase-Control StudiesEthnicityGenetic Predisposition to DiseaseGenomicsHumansINDEL MutationMaleMiddle AgedPolymorphism, Single NucleotideProstatic NeoplasmsQuantitative Trait LociBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.